About This Deal

Gilead Sciences acquired Forty Seven, Inc. for ~$4.9 billion, a transaction announced in March 2020.

Acquired the immuno-oncology company for $95.50 per share in cash to strengthen Gilead's oncology pipeline, gaining lead anti-CD47 antibody magrolimab in development for myelodysplastic syndrome, AML and DLBCL.

Acquired the immuno-oncology company for $95.50 per share in cash to strengthen Gilead's oncology pipeline, gaining lead anti-CD47 antibody magrolimab in development for myelodysplastic syndrome, AML and DLBCL.

Deal Terms

Acquirer
Gilead Sciences
Target
Forty Seven, Inc.
Value
~$4.9 billion
Date
March 2020
Type
Full acquisition
Status
Completed

Transaction Details

Announced
March 2, 2020

Advisors

Advisory firms were not disclosed for this transaction.

Related Deals & Entities

Sources: Press release ↗

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.